腫瘍治療薬の日本市場:化学療法、標的療法、免疫療法、ホルモン療法...市場調査レポートについてご紹介

【英文タイトル】Japan Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019–2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018

3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Rise In Incidence of Cancer
3.4.1.2. Surge In Geriatric Population

3.4.2. Restraint

3.4.2.1. Stringent Approval Process

3.4.3. Opportunity

3.4.3.1. Increase In Number of Pipeline Drugs

3.4.4. Impact Analyses

Chapter 4: Oncology Drugs Market, By Drug Class Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Chemotherapy

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast,

4.3. Targeted Therapy

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast,

4.4. Immunotherapy

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast,

4.5. Hormonal Therapy

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast,

Chapter 5: Oncology Drugs Market, By Indication

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Blood Cancer

5.2.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities
5.2.2. Market Size And Forecast

5.3. Breast Cancer

5.3.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities
5.3.2. Market Size And Forecast

5.4. Gastrointestinal And Urinary Cancer

5.4.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.4.1.1. Market Size And Forecast

5.4.2. Gb/Cholangiocarcinoma

5.4.2.1. Market Size And Forecast

5.4.3. Bladder Cancer

5.4.3.1. Market Size And Forecast

5.4.4. Pancreatic Cancer

5.4.4.1. Market Size And Forecast

5.5. Prostate Cancer

5.5.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.5.1.1. Market Size And Forecast

5.6. Lung Cancer

5.6.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.6.1.1. Market Size And Forecast

5.6.2. Small Cell Lung Cancer

5.6.2.1. Market Size And Forecast

5.7. Skin Cancer

5.7.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.7.1.1. Market Size And Forecast

5.8. Ovarian Cancer

5.8.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.8.1.1. Market Size And Forecast

5.9. Cervical Cancer

5.9.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.9.1.1. Market Size And Forecast

5.10. Kidney Cancer

5.10.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.10.1.1. Market Size And Forecast

5.11. Other Cancers

5.11.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.11.1.1. Market Size And Forecast

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance
6.1.6. Key Strategic Moves And Developments: Global

6.2. Astellas Pharma Inc.

6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance
6.2.6. Key Strategic Moves And Developments: Japan
6.2.7. Key Strategic Moves And Developments: Global

6.3. Astrazeneca Plc

6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance
6.3.6. Key Strategic Moves And Developments: Japan
6.3.7. Key Strategic Moves And Developments: Global

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments: Global

6.5. Celgene Corporation

6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments: Global

6.6. Daiichi Sankyo Company, Limited

6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments: Japan
6.6.7. Key Strategic Moves And Developments: Global

6.7. Hoffmann-La Roche Ag

6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments: Japan
6.7.7. Key Strategic Moves And Developments: Global

6.8. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments: Japan
6.8.7. Key Strategic Moves And Developments: Global

6.9. Otsuka Holdings Co., Ltd.

6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments: Japan
6.9.7. Key Strategic Moves And Developments: Global

6.10. Takeda Pharmaceutical Company Ltd.

6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Business Performance
6.10.6. Key Strategic Moves And Developments: Japan
6.10.7. Key Strategic Moves And Developments: Global


【レポート販売概要】

■ タイトル:腫瘍治療薬の日本市場:化学療法、標的療法、免疫療法、ホルモン療法
■ 英文:Japan Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy), and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019–2026
■ 発行日:2019年8月
■ 調査会社:Allied Market Research
■ 商品コード:AMR9NV118
■ 調査対象地域:日本
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。